New Carbon Monoxide Medicines for Acute Kidney Injury
Early-Stage Preclinical Validation of Carbon Monoxide Prodrugs for Acute Kidney Injury
This research explores new carbon monoxide-based medicines to help patients with acute kidney injury, a serious condition with limited treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11164581 on NIH RePORTER |
What this research studies
We are developing innovative medications that deliver carbon monoxide in a safe and controlled way, aiming to protect organs and reduce inflammation. Our approach builds on existing knowledge about carbon monoxide's natural protective effects in the body. We are testing these new 'prodrugs' in various animal models, including larger animals, to ensure they are effective and safe. The goal is to identify promising drug candidates that can move closer to human testing.
Who could benefit from this research
Good fit: This early-stage research is focused on developing new treatments for patients who experience acute kidney injury.
Not a fit: Patients with chronic kidney disease or other kidney conditions not involving acute injury may not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this work could lead to the first disease-modifying treatment for acute kidney injury, offering a new option beyond current supportive care.
How similar studies have performed: While carbon monoxide's protective effects are known, this specific approach of delivering it through innovative prodrugs is a novel and promising strategy.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Wang, Binghe — Georgia State University
- Study coordinator: Wang, Binghe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.